HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages.
HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages
HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages
HDT Bio’s proprietary technologies harness the immune system to combat difficult-to-treat conditions and improve patient lives worldwide.
The next generation of formulations
HDT’s LION™ technology provides increased potency compared to traditional formulations – increasing safety, tolerability, immunogenicity, and manufacturability.
Latest News
HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
SEATTLE, May 21, 2026 /PRNewswire/ -- HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington, today announced that it received the Medical CBRN Defense Consortium (MCDC) Innovation Prototype Award. The award recognizes HDT Bio's MCDC project...
FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
SEATTLE, Sept. 19, 2025 /PRNewswire/ -- HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has...
MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
HDT Bio's LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid...